Patent Examiner Jacob A. Boeckelman
Art Unit 1655 · Plant, Fungal & Animal-Derived Extracts · Tech Center 1600 · 266 applications filed 2021–2026
Jacob A. Boeckelman is a USPTO patent examiner in Art Unit 1655 (Plant, Fungal & Animal-Derived Extracts) with 266 applications from filing years 2021–2026. Examiner Boeckelman's allowance rate is 36.7%, below the 81.5% USPTO average for applications filed in the same years. The examiner ranks harder than 94% of examiners. In 2021, decided applications with an examiner interview were allowed 62.2 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1655 · Plant, Fungal & Animal-Derived Extracts
- Title / gradePatent Examiner · GS-13
- Service6 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsBOECKELMAN, JACOB A
How to improve your odds with Examiner Boeckelman
- The data favors an interview. Interviewed cases were allowed more often in both measured years, by 43.1 to 62.2 points.
- Plan for the timeline. First office action averages 758 days vs the 624-day USPTO norm.
- Expect a §103. Obviousness is the most-issued rejection (273), and applicants overcame it 26.8% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 29.5 to 29.9 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 19 winning responses to Examiner Boeckelman's §103 rejections that Boundly has classified, 18 (95%) amended the claims and argued, and 1 argued without amending. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Boeckelman?
Draft your response with Examiner Boeckelman's record and Art Unit 1655's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 30.4% | 68.8% | 25.7% | +43.1pp |
| 2021 | 34.2% | 76.2% | 14.0% | +62.2pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Boeckelman.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 38.0% | 61.5% | 31.6% | +29.9pp |
| 2021 | 34.2% | 55.6% | 26.1% | +29.5pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/275643 | Composition Containing Black Ginseng as Active Ingredient for Prevention, Alleviation, or Treatment of Coronavirus Infection | Abandoned | 0 | 🔒 View |
| 18/278227 | Composition for Strengthening, Developing, Differentiating, or Regenerating Muscle, or Preventing, Ameliorating, or Treating Muscle Loss or Muscle Fatigue Comprising Schizonepeta tenuifolia Extract as Effective Component | Patented | 1 | 🔒 View |
| 18/380875 | Method for Extracting and Purifying Total Flavonoids from Carthamus tinctorius L. Leaf (TFFCL), and Use Thereof | Abandoned | 1 | 🔒 View |
| 17/665037 | Autologous Thymic Tissue Transplantation | Abandoned | 4 | 🔒 View |
Art Unit 1655 technology
Frequently asked questions
What is Examiner Jacob A. Boeckelman's allowance rate?
Is Examiner Boeckelman a hard examiner?
Do examiner interviews help with Examiner Boeckelman?
What is Examiner Boeckelman's most common rejection?
Is an RCE worth filing with Examiner Boeckelman?
How long until the first office action from Examiner Boeckelman?
How do I contact Examiner Jacob A. Boeckelman?
Put Examiner Boeckelman's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.